India-Made AIDS Vaccine Passes Initial Trials
This article was originally published in PharmAsia News
Executive Summary
An AIDS vaccine developed in India has passed Phase I trials, according to agencies involved. The candidate drug, TBC-M4, was shown to be 100 percent effective in boosting the immune response in humans to AIDS. Three groups, the Indian Council of Medical Research, the National AIDS Control Organisation and the International AIDS Vaccine Initiative are involved in the trials. The drug is based on modified vaccine Ankara virus, also being test by Bavarian Nordic as a smallpox vaccine. (Click here for more
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.